The emergence of resistance to targeted cancer therapeutics (Q34837015)

4 August 2017

1 reference

title

The emergence of resistance to targeted cancer therapeutics (English)

1 reference

4 August 2017

Ingo K Mellinghoff

1

1 reference

PubMed ID

12223047

4 August 2017

Charles L Sawyers

series ordinal

2

1 reference

PubMed ID

12223047

4 August 2017

language of work or name

1 reference

1 September 2002

1 reference

4 August 2017

1 reference

4 August 2017

3

1 reference

4 August 2017

603-623

1 reference

4 August 2017

5

1 reference

The Evolution of Therapeutic Research in Cancer

4 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

New-age drug meets resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Basis for differential cellular sensitivity to 8-azaguanine and 6-thioguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Topoisomerase I inhibitors: selectivity and cellular resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Tumor cell resistance to DNA topoisomerase II inhibitors: new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Prostate cancer: a brief history and the discovery of hormonal ablation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

The nuclear receptor ligand-binding domain: structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Androgen receptors in endocrine-therapy-resistant human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Genetic alterations of androgen receptor gene in Japanese human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Androgen receptor alterations in patients with disturbances in male sexual development and in prostatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Androgen receptor gene mutations in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Activation of the human androgen receptor through a protein kinase A signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Intrinsic and acquired resistance to methotrexate in acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

MRP3, an organic anion transporter able to transport anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Early appearance and long-term persistence of the submicroscopic extrachromosomal elements (amplisomes) containing the amplified DHFR genes in human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Unstable Methotrexate Resistance in Human Small-Cell Carcinoma Associated with Double Minute Chromosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Gene amplification in a leukemic patient treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Resistance to methotrexate due to gene amplification in a patient with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Parasitology. When the host is smarter than the parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

A PMLRARalpha transgene initiates murine acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Translocations of the RARalpha gene in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Acute promyelocytic leukemia: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Essential role for oncogenic Ras in tumour maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Reversible tumorigenesis by MYC in hematopoietic lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Pharmacogenetics and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Thymineless death in colon carcinoma cells is mediated via fas signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Death and anti-death: tumour resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Two CD95 (APO-1/Fas) signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Genetic analysis of chemoresistance in primary murine lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Inhibition of death receptor signals by cellular FLIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Role of BAX in the apoptotic response to anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

The multiple roles of PTEN in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Use of isogenic human cancer cells for high-throughput screening and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Cancer modeling in the modern era: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Molecular classification of cutaneous malignant melanoma by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.3.5.603

21 January 2018

Identifiers

DOI

10.1517/14622416.3.5.603

1 reference

4 August 2017

1 reference

PubMed ID

12223047